Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 7/2018

Open Access 01-07-2018 | Original Research Article

Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database

Authors: Sophie Billioti de Gage, Cédric Collin, Thien Le-Tri, Antoine Pariente, Bernard Bégaud, Hélène Verdoux, Rosemary Dray-Spira, Mahmoud Zureik

Published in: CNS Drugs | Issue 7/2018

Login to get access

Abstract

Background

Hepatotoxicity may be a concern when prescribing antidepressants. Nevertheless, this risk remains poorly understood for serotonin and noradrenaline reuptake inhibitors (SNRIs: venlafaxine, milnacipran, duloxetine) and ‘other antidepressants’ (mianserin, mirtazapine, tianeptine and agomelatine), particularly in comparison with selective serotonin reuptake inhibitors (SSRIs: fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, escitalopram), which are by far the most commonly prescribed antidepressants.

Objective

We quantified the risk of serious liver injury associated with new use of SNRIs and ‘other antidepressants’ compared with SSRIs in real-life practice.

Methods

Based on the French national health insurance database, this cohort study included 4,966,825 individuals aged 25 years and older with a first reimbursement of SSRIs, SNRIs or ‘other antidepressants’ between January 2010 and June 2015. We compared the risk of serious liver injury within the 6 months following antidepressant initiation according to antidepressant class, with SSRIs as the reference, using an inverse probability-of-treatment-weighted Cox proportional hazard model adjusted for demographic characteristics and risk factors of liver injury.

Results

We identified 382 serious liver injuries overall (none for milnacipran initiators). Age and gender standardized incidence rates per 100,000 person-years were 19.2 for SSRIs, 22.2 for venlafaxine, 12.6 for duloxetine, 21.5 for mianserin, 32.8 for mirtazapine, 31.6 for tianeptine and 24.6 for agomelatine initiators. Initiation of antidepressants of interest versus SSRIs was not associated with an increased risk of serious liver injury [adjusted hazard ratios (95% confidence interval): venlafaxine 1.17 (0.83–1.64), duloxetine 0.54 (0.28–1.02), mianserin 0.90 (0.58–1.41), mirtazapine 1.17 (0.67–2.02), tianeptine 1.35 (0.82–2.23) and agomelatine 1.07 (0.51–2.23)]. This finding was confirmed by the results of an additional study using a case-time-control design.

Conclusion

These results do not provide evidence of an increased risk of serious liver injury following initiation of SNRIs or ‘other antidepressants’ compared with SSRIs in real-life practice. This could reflect an inherent lack of difference in risk between the drug classes, or the fact that individuals with higher susceptibility to drug-induced liver injury are not prescribed drugs considered to be more hepatotoxic.
Appendix
Available only for authorised users
Literature
1.
Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SHB, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–54.CrossRefPubMed
2.
3.
Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–5.CrossRefPubMed
4.
Björnsson E, Bergmann O, Björnsson H, Kvaran R, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–25.CrossRefPubMed
5.
Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014;171:404–15.CrossRefPubMed
6.
Friedrich M-E, Akimova E, Huf W, Konstantinidis A, Papageorgiou K, Winkler D, et al. Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program. Int J Neuropsychopharmacol. 2016;19(4):1–9.CrossRef
7.
Wernicke J, Pangallo B, Wang F, Murray I, Henck JW, Knadler MP, et al. Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf. 2008;3:132–42.CrossRefPubMed
8.
9.
Lin ND, Norman H, Regev A, Perahia DG, Li H, Chang CL, et al. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. BMC Gastroenterol. 2015;15:134.CrossRefPubMedPubMedCentral
10.
Xue F, Strombom I, Turnbull B, Zhu S, Seeger JD. Duloxetine for depression and the incidence of hepatic events in adults. J Clin Psychopharmacol. 2011;31:517–22.CrossRefPubMed
11.
Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–86.CrossRefPubMedPubMedCentral
12.
Weill A, Dalichampt M, Raguideau F, Ricordeau P, Blotière P-O, Rudant J, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016;353:i2002.CrossRefPubMedPubMedCentral
13.
Raguideau F, Lemaitre M, Dray-Spira R, Zureik M. Association between oral fluoroquinolone use and retinal detachment. JAMA Ophthalmol. 2016;134:415–21.CrossRefPubMed
14.
Bouillon K, Bertrand M, Boudali L, Ducimetière P, Dray-Spira R, Zureik M. Short-term risk of bleeding during heparin bridging at initiation of vitamin K antagonist therapy in more than 90,000 patients with nonvalvular atrial fibrillation managed in outpatient care. J Am Heart Assoc. 2016;5(11):e004065.CrossRefPubMedPubMedCentral
15.
Colas S, Collin C, Piriou P, Zureik M. Association between total hip replacement characteristics and 3-year prosthetic survivorship: a population-based study. JAMA Surg. 2015;150:979–88.CrossRefPubMed
16.
Bouillon K, Bertrand M, Maura G, Blotière P-O, Ricordeau P, Zureik M. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol. 2015;2:e150–9.CrossRefPubMed
17.
Maura G, Blotière P-O, Bouillon K, Billionnet C, Ricordeau P, Alla F, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation. 2015;132:1252–60.CrossRefPubMedPubMedCentral
18.
Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Das K. The feasibility of studying drug-induced acute hepatitis with use of Medicaid data. Clin Pharmacol Ther. 1992;52:214–9.CrossRefPubMed
19.
Lo Re V III, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KBF, et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration’s Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf. 2013;22:861–72.CrossRefPubMedPubMedCentral
20.
Lo Re V III, Carbonari DM, Forde KA, Goldberg D, Lewis JD, Haynes K, et al. Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiol Drug Saf. 2015;24:676–83.CrossRefPubMed
21.
Udo R, Maitland-van der Zee AH, Egberts TCG, den Breeijen JH, Leufkens HGM, van Solinge WW, et al. Validity of diagnostic codes and laboratory measurements to identify patients with idiopathic acute liver injury in a hospital database. Pharmacoepidemiol Drug Saf. 2015;25(Suppl-1):21–8.PubMed
22.
Rey G, Jougla E, Fouillet A, Hémon D. Ecological association between a deprivation index and mortality in France over the period 1997–2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:33.CrossRefPubMedPubMedCentral
23.
24.
Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010;33:503–22.CrossRefPubMed
25.
Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242–58.CrossRefPubMed
26.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–79.CrossRefPubMedPubMedCentral
27.
Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149–56.CrossRefPubMedPubMedCentral
28.
29.
Sparshatt A, McAllister Williams RH, Baldwin DS, Haddad PM, Bazire S, Weston E, et al. A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks. Acta Psychiatr Scand. 2013;128:203–11.CrossRefPubMed
30.
Laux G, VIVALDI Study. Group. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry. 2012;45:284–91.CrossRef
31.
Gahr M, Zeiss R, Lang D, Connemann BJ, Schonfeldt-Lecuona C. Hepatotoxicity associated with agomelatine and other antidepressants: disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre. J Clin Pharmacol. 2015;55:768–73.CrossRefPubMed
32.
Gahr M, Zeiss R, Lang D, Connemann BJ, Hiemke C, Schonfeldt-Lecuona C. Drug-induced liver injury associated with antidepressive psychopharmacotherapy: an explorative assessment based on quantitative signal detection using different MedDRA terms. J Clin Pharmacol. 2016;56(6):769–78.CrossRefPubMed
33.
Macaigne G, Auriault M-L, Chayette C, Cheiab S, Deplus R. Tianeptine induced acute hepatitis. Gastroenterologie clinique et biologique. 2003;27:348–9.PubMed
34.
Le Bricquir Y, Larrey D, Blanc P, Pageaux GP, Michel H. Tianeptine—an instance of drug-induced hepatotoxicity predicted by prospective experimental studies. J Hepatol. 1994;21:771–3.CrossRefPubMed
35.
Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther. 1995;67:101–54.CrossRefPubMed
36.
Stadlmann S, Portmann S, Tschopp S, Terracciano LM. Venlafaxine-induced cholestatic hepatitis: case report and review of literature. Am J Surg Pathol. 2012;36:1724–8.CrossRefPubMed
37.
Phillips BB, Digmann RR, Beck MG. Hepatitis associated with low-dose venlafaxine for postmenopausal vasomotor symptoms. Ann Pharmacother. 2006;40:323–7.CrossRefPubMed
38.
Hui C-K, Yuen M-F, Wong W-M, Lam S-K, Lai C-L. Mirtazapine-induced hepatotoxicity. J Clin Gastroenterol. 2002;35:270–1.CrossRefPubMed
39.
Kang S-G, Yoon B-M, Park Y-M. Mirtazapine-induced hepatocellular-type liver injury. Ann Pharmacother. 2011;45:825–6.CrossRefPubMed
40.
Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98:253–9.CrossRefPubMedPubMedCentral
41.
Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221–8.CrossRefPubMedPubMedCentral
Metadata
Title
Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database
Authors
Sophie Billioti de Gage
Cédric Collin
Thien Le-Tri
Antoine Pariente
Bernard Bégaud
Hélène Verdoux
Rosemary Dray-Spira
Mahmoud Zureik
Publication date
01-07-2018
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 7/2018
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-018-0537-1

Other articles of this Issue 7/2018

CNS Drugs 7/2018 Go to the issue

Adis Drug Evaluation

Nusinersen: A Review in 5q Spinal Muscular Atrophy

Leading Article

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention

Review Article

Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond

Original Research Article

Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration?

Original Research Article

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study

Letter to the Editor

Author’s Reply to Segura-Aguilar: Autophagosome maturation not autophagy induction is impaired in neurodegeneration